• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Acta Obstet Gynecol Scand . Shared risk factors for COVID-19 and preeclampsia in the first trimester: An observational study

tetano

Editor, Senior Moderator
Acta Obstet Gynecol Scand


. 2022 May 3.
doi: 10.1111/aogs.14371. Online ahead of print.
Shared risk factors for COVID-19 and preeclampsia in the first trimester: An observational study


Berta Serrano[SUP] 1 [/SUP], Manel Mendoza[SUP] 1 [/SUP], Paula Garcia-Aguilar[SUP] 1 [/SUP], Erika Bonacina[SUP] 1 [/SUP], Itziar Garcia-Ruiz[SUP] 1 [/SUP], Pablo Garcia-Manau[SUP] 1 [/SUP], Judit Gil[SUP] 1 [/SUP], Mireia Armengol-Alsina[SUP] 1 [/SUP], Nuria Fernandez-Hidalgo[SUP] 2 [/SUP], Elena Sulleiro[SUP] 3 [/SUP], Rosa Maria Lopez-Martinez[SUP] 4 [/SUP], Marta Ricart[SUP] 5 [/SUP], Lourdes Martin[SUP] 6 [/SUP], Eva Lopez-Quesada[SUP] 7 [/SUP], Angels Vives[SUP] 8 [/SUP], Anna Maroto[SUP] 9 [/SUP], Nerea Maiz[SUP] 1 [/SUP], Anna Suy[SUP] 1 [/SUP], Elena Carreras[SUP] 1 [/SUP]



Affiliations

Abstract

Introduction: The association between preeclampsia and coronavirus disease 2019 (COVID-19) is under study. Previous publications have hypothesized the existence of shared risk factors for both conditions or a deficient trophoblastic invasion as possible explanations for this association. The primary aim of this study was to examine baseline risk factors measured in the first-trimester combined screening for preeclampsia in pregnant women with COVID-19 compared with the general population. A secondary aim of this study was to compare risk factors among patients with mild and severe COVID-19.
Material and methods: This was an observational retrospective study conducted at Vall d'Hebron Hospital Campus (Catalonia, Spain). Study patients were 231 pregnant women undergoing the first-trimester screening for preeclampsia and positive for severe acute respiratory syndrome coronavirus 2 between February 2020 and September 2021. The reference cohort were 13 033 women of the general population from six centers across Catalonia from May 2019 to June 2021. Based on the need for hospitalization, patients were classified in two groups: mild and severe COVID-19. First-trimester screening for preeclampsia included maternal history, mean arterial blood pressure, mean uterine artery pulsatility index (UtAPI), placental growth factor (PlGF), and pregnancy-associated plasma protein-A (PAPP-A).
Results: The proportion of cases at high risk for preeclampsia was significantly higher among the COVID-19 group compared with the general population (19.0% and 13.2%, respectively; p = 0.012). When analyzing risk factors for preeclampsia individually, women with COVID-19 had higher median body mass index (25.2 vs. 24.5, p = 0.041), higher UtAPI multiple of the median (MoM) (1.08 vs. 1.00, p < 0.001), higher incidence of chronic hypertension (2.8% vs. 0.9%, p = 0.015), and there were fewer smokers (5.7% vs. 11.6%, p = 0.007). The MoMs of PlGF and PAPP-A did not differ significantly between both groups (0.96 vs. 0.97, p = 0.760 and 1.00 vs. 1.01, p = 0.432; respectively).
Conclusions: In patients with COVID-19, there was a higher proportion of women at high risk for preeclampsia at the first-trimester screening than in the general population, mainly because of maternal risk factors, rather than placental signs of a deficient trophoblastic invasion.

Keywords: coronavirus disease 2019; first trimester; placental growth factor; preeclampsia; risk factors; screening; severe acute respiratory syndrome coronavirus 2; uterine artery Doppler.
 
Back
Top Bottom